Ghrelin-receptor agonism.
Acting on the ghrelin / GH-secretagogue receptor, a pathway separate from GHRH.
The growth hormone secretagogue receptor, GHS-R1a, is a G-protein-coupled receptor expressed on pituitary somatotrophs and in hypothalamic nuclei. Its natural ligand is ghrelin, the stomach-derived hormone associated with hunger. Activation raises growth hormone through a route entirely separate from GHRH: it acts directly on somatotrophs, and it also suppresses hypothalamic somatostatin tone, effectively releasing the brake at the same time as pressing the accelerator. This dual action is why compounds at this receptor and GHRH analogs are often studied together, since combining them produces a larger growth hormone response than either produces alone. The history here is unusual. The synthetic peptides in this group were developed in the 1980s and 1990s by working backwards from observed growth hormone release, years before ghrelin itself was identified in 1999. They were the pharmacological tools that led researchers to the receptor. They are therefore best understood as synthetic ghrelin mimetics that happened to be discovered before the hormone they mimic. Members of this group differ chiefly in selectivity, which is the practical distinction that matters most. GHS-R1a activation is not confined to growth hormone. Because the receptor sits on cells that also govern prolactin and adrenocorticotropic hormone release, and because ghrelin signalling drives appetite and influences gastric motility, several of these compounds raise cortisol and prolactin and increase hunger alongside the intended growth hormone effect. Others were specifically designed to avoid that, producing a comparatively clean growth hormone response with minimal spillover onto the other axes. Some also show additional activity at the CD36 receptor, which has been studied in cardiac contexts. Honest assessment of clinical relevance: the acute receptor pharmacology is well characterised, including in short human studies where growth hormone reliably rises after administration. That is proof of mechanism. What does not exist for this class is proof of benefit. No compound in this group is an approved medicine, controlled trials of sustained use with body composition or clinical endpoints are essentially absent, and material sold under these names is unregulated research-grade product of uncertain content. Growth hormone secretagogues are also prohibited in sport by anti-doping authorities. A further consideration specific to this receptor is desensitisation: sustained agonism at a G-protein-coupled receptor commonly reduces its responsiveness over time, so the acute hormonal response observed in a short study is not a reliable guide to what happens with continued use.
Peptides acting through this pathway.
FAQ.
What does ghrelin-receptor agonism do?
The growth hormone secretagogue receptor, GHS-R1a, is a G-protein-coupled receptor expressed on pituitary somatotrophs and in hypothalamic nuclei. Its natural ligand is ghrelin, the stomach-derived hormone associated with hunger. Activation raises growth hormone through a route entirely separate from GHRH: it acts directly on somatotrophs, and it also suppresses hypothalamic somatostatin tone, effectively releasing the brake at the same time as pressing the accelerator. This dual action is why compounds at this receptor and GHRH analogs are often studied together, since combining them produces a larger growth hormone response than either produces alone. The history here is unusual. The synthetic peptides in this group were developed in the 1980s and 1990s by working backwards from observed growth hormone release, years before ghrelin itself was identified in 1999. They were the pharmacological tools that led researchers to the receptor. They are therefore best understood as synthetic ghrelin mimetics that happened to be discovered before the hormone they mimic. Members of this group differ chiefly in selectivity, which is the practical distinction that matters most. GHS-R1a activation is not confined to growth hormone. Because the receptor sits on cells that also govern prolactin and adrenocorticotropic hormone release, and because ghrelin signalling drives appetite and influences gastric motility, several of these compounds raise cortisol and prolactin and increase hunger alongside the intended growth hormone effect. Others were specifically designed to avoid that, producing a comparatively clean growth hormone response with minimal spillover onto the other axes. Some also show additional activity at the CD36 receptor, which has been studied in cardiac contexts. Honest assessment of clinical relevance: the acute receptor pharmacology is well characterised, including in short human studies where growth hormone reliably rises after administration. That is proof of mechanism. What does not exist for this class is proof of benefit. No compound in this group is an approved medicine, controlled trials of sustained use with body composition or clinical endpoints are essentially absent, and material sold under these names is unregulated research-grade product of uncertain content. Growth hormone secretagogues are also prohibited in sport by anti-doping authorities. A further consideration specific to this receptor is desensitisation: sustained agonism at a G-protein-coupled receptor commonly reduces its responsiveness over time, so the acute hormonal response observed in a short study is not a reliable guide to what happens with continued use.
Which peptides act through ghrelin-receptor agonism?
Ipamorelin, Hexarelin, GHRP-2, GHRP-6, GHRP-1. They share this pathway but differ in evidence, approval, and safety.
Does this mechanism prove a peptide works?
No. Mechanistic plausibility is not proof of clinical benefit. A plausible pathway is a reason to study a compound, not evidence that it works in humans.